Arqule

Encouraging Phase 1 data with lead compound, ARQ 092, to be presented at AACR

Encouraging Phase 1 data with lead compound, ARQ 092, to be presented at AACR

Yahoo

ArQule Earnings: Everything You Must Know Now

ArQule Earnings: Everything You Must Know Now

Wall St. Cheat Sheet

ArQule enrolls first patient in Phase 3 trial for carcinoma candidate tivantinib

ArQule enrolls first patient in Phase 3 trial for carcinoma candidate tivantinib

Yahoo/Fly on the Wall

Latest Tivantinib Failure Hits ArQule Despite Its Irrelevance

Latest Tivantinib Failure Hits ArQule Despite Its Irrelevance

Seeking Alpha

3 Horrendous Health-Care Stocks This Week

3 Horrendous Health-Care Stocks This Week

Motley Fool

Biotech Portfolio Update: 2012 Summary And 2013 Outlook

Biotech Portfolio Update: 2012 Summary And 2013 Outlook

Seeking Alpha

ArQule: An Inexpensive And Well-Financed Oncology Opportunity

ArQule: An Inexpensive And Well-Financed Oncology Opportunity

Seeking Alpha

3 Biotechs With Good FDA News

3 Biotechs With Good FDA News

Motley Fool

ArQule's Tivantinib Failure And Exelixis' Cabozantinib PDUFA: Is There A Correlation?

ArQule's Tivantinib Failure And Exelixis' Cabozantinib PDUFA: Is There A Correlation?

Seeking Alpha

Weekend Recap: Biotech Madness

Weekend Recap: Biotech Madness

Seeking Alpha